source boundary
frontier-owneddeclared
A source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
frontiers / frontier
Source record
back to sourcessource boundary
frontier-ownedA source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
finding bindings
record contextFindings bound to this source through source ids, evidence atoms, provenance, or reviewed source-record slots.
evidence atoms
materializedEvidence atoms pin exact spans, measurements, selectors, or curation assertions to the source.
review context
inspectable1 reviewable changes and 0 evaluations are attached through this source or its findings.
Locator and citation
locator
title:Maude et al. NEJM 2018 (tisagenlecleucel pediatric ALL); Neelapu et al. NEJM 2017 (axi-cel DLBCL)
imported
2026-05-09T22:24:02.847953+00:00
extraction mode
manual_curation
authors
agent:immuno-research-bot-2026-05-09
Caveats
No source-specific caveats are recorded.
CD19 CAR-T (tisagenlecleucel, axicabtagene ciloleucel) produced complete responses in 70-90 percent of relapsed/refractory pediatric ALL and 40-60 percent of refractory DLBCL in pivotal trials; B-cell aplasia and cytokine release syndrome are the dominant toxicities. The class established CAR-T as a treatment modality for hematologic malignancies.
events
vev_66e28575892e7972finding.assertedManual finding added to frontier state
agent:immuno-research-bot-2026-05-09 · 2026-05-09
reviewable changes
vpr_2496f7eb56a7dd9ffinding.addManual finding added to frontier state
applied · agent:immuno-research-bot-2026-05-09 · 2026-05-09
evaluations
No evaluation rows are attached.